Compare GSK plc (GSK) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Live Nation Entertainment, Inc. — how do they compare? GSK plc trades at $46.63 (market cap $91.88B), while Live Nation Entertainment, Inc. trades at $171.86 (market cap $39.92B). The key difference: GSK plc is far larger — about 2.3× Live Nation Entertainment, Inc.'s market cap, and GSK plc pays a 3.9% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Live Nation Entertainment, Inc. for 72 Days on average.
| GSK | LYV | |
|---|---|---|
Market Cap | $91.88B | $39.92B |
Volume | 7,730,529 | 1,982,609 |
Sector | Health | Media |
52-Week High | $61.18 | $188.46 |
52-Week Low | $43.24 | $125.61 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $111.88B | $42.13B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
LYV trades at $172.10, up 0.74% today, with a bullish technical signal and strong analyst support. Revenue grew to $25.20B in 2025, though net income margin narrowed to 1.96%. Recent news highlights robust fan demand and strategic partnerships, while the stock faces high valuation multiples and regulatory scrutiny.
Outlook remains positive with a consensus price target of $208.18, but risks include elevated P/E of 117.49, debt levels, and legal uncertainties. Earnings momentum is mixed, with Q2 2026 beating estimates but Q1 and Q4 2025 missing, underscoring execution challenges amid growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
